SERA PROGNOSTICS, INC.
SERANasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $81,000 | $77,000 | $306,000 | $268,000 | $82,000 | $25,000 |
| Operating income | −$36.5M | −$36.6M | −$39.8M | −$45.7M | −$35.4M | −$18.0M |
| Net income | −$31.9M | −$32.9M | −$36.2M | −$44.2M | −$35.0M | −$19.8M |
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147.0M | $14.8M |
| Total liabilities | $26.5M | $24.8M | $25.3M | $17.4M | $8.5M | $12.3M |
| Equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M | −$125.6M |
| EPS (diluted) | $-0.67 | $-0.99 | $-1.16 | $-1.43 | $-2.33 | $-12.76 |
| Shares out. | 47.7M | 33.2M | 31.2M | 30.9M | 15.0M | 1.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −45066.7%
- Net margin
- −39417.3%
- Return on equity
- −42.3%
- Return on assets
- −31.3%
- Return on capital (ROCE)
- −47.0%
- Liabilities / assets
- 26.0%
- Debt / equity
- 0.35×
- Book value / share
- $1.58
- Revenue growth (YoY)
- 5.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -8.32distress
- Accruals / assets
- −6.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jackson BenjaminOfficer — General Counsel | May 29, 2026 | Grant | 5,000 | $1.84 |
| Anderson Dyaarl Lee Jr.Officer — Chief Commercial Officer | May 29, 2026 | Grant | 3,168 | $1.84 |
| Lindgardt ZhenyaOfficer — Chief Executive Officer | Mar 12, 2026 | Grant | 154,440 | $0.00 |
| Jackson BenjaminOfficer — General Counsel | Mar 12, 2026 | Grant | 44,215 | $0.00 |
| Inglis Tiffany Eul DavisOfficer — Chief Medical Officer | Mar 12, 2026 | Grant | 17,437 | $0.00 |
| Anderson Dyaarl Lee Jr.Officer — Chief Commercial Officer | Mar 12, 2026 | Grant | 12,455 | $0.00 |
| Aerts AustinOfficer — Chief Financial Officer | Mar 12, 2026 | Grant | 44,215 | $0.00 |
| Lindgardt ZhenyaOfficer — Chief Executive Officer | Mar 10, 2026 | Sell | 22,639 | $1.90 |
| Kearney PaulOfficer — Chief Data Officer | Mar 11, 2026 | Sell | 1,396 | $2.04 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 280,984 | 4.2 | -5.8% |
| Apr 30, 2026 | 298,294 | 19.7 | -14.2% |
| Apr 15, 2026 | 347,818 | 10.7 | -8.8% |
| Mar 31, 2026 | 381,493 | 4.6 | +54.2% |
| Mar 13, 2026 | 247,469 | 2.2 | -12.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeJun 1, 2026
- Results of operationsMay 6, 2026
- Results of operationsMar 18, 2026
- Regulation FD disclosureJan 8, 2026
- Regulation FD disclosureJan 7, 2026
- Regulation FD disclosureNov 24, 2025
- Results of operationsNov 13, 2025
- Regulation FD disclosureSep 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.